GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Progenics Pharmaceuticals Inc (NAS:PGNX) » Definitions » Days Inventory

Progenics Pharmaceuticals (Progenics Pharmaceuticals) Days Inventory : 0.00 (As of Mar. 2020)


View and export this data going back to 1997. Start your Free Trial

What is Progenics Pharmaceuticals Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Progenics Pharmaceuticals's Average Total Inventories for the three months ended in Mar. 2020 was $0.00 Mil. Progenics Pharmaceuticals's Cost of Goods Sold for the three months ended in Mar. 2020 was $1.56 Mil. Hence, Progenics Pharmaceuticals's Days Inventory for the three months ended in Mar. 2020 was 0.00.

The historical rank and industry rank for Progenics Pharmaceuticals's Days Inventory or its related term are showing as below:

PGNX's Days Inventory is not ranked *
in the Biotechnology industry.
Industry Median: 192.335
* Ranked among companies with meaningful Days Inventory only.

Progenics Pharmaceuticals's Days Inventory stayed the same from Mar. 2019 (0.00) to Mar. 2020 (0.00).

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Progenics Pharmaceuticals's Inventory-to-Revenue for the three months ended in Mar. 2020 was 0.00.


Progenics Pharmaceuticals Days Inventory Historical Data

The historical data trend for Progenics Pharmaceuticals's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progenics Pharmaceuticals Days Inventory Chart

Progenics Pharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Days Inventory
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Progenics Pharmaceuticals Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
Days Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Progenics Pharmaceuticals's Days Inventory

For the Biotechnology subindustry, Progenics Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Progenics Pharmaceuticals's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Progenics Pharmaceuticals's Days Inventory distribution charts can be found below:

* The bar in red indicates where Progenics Pharmaceuticals's Days Inventory falls into.



Progenics Pharmaceuticals Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Progenics Pharmaceuticals's Days Inventory for the fiscal year that ended in Dec. 2019 is calculated as

Days Inventory (A: Dec. 2019 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (A: Dec. 2018 ) + Total Inventories (A: Dec. 2019 )) / count ) / Cost of Goods Sold (A: Dec. 2019 )*Days in Period
=( (0 + 0) / 1 ) / 3.168*365
=0 / 3.168*365
=0.00

Progenics Pharmaceuticals's Days Inventory for the quarter that ended in Mar. 2020 is calculated as:

Days Inventory (Q: Mar. 2020 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (Q: Dec. 2019 ) + Total Inventories (Q: Mar. 2020 )) / count ) / Cost of Goods Sold (Q: Mar. 2020 )*Days in Period
=( (0 + 0) / 1 ) / 1.558*365 / 4
=0 / 1.558*365 / 4
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Progenics Pharmaceuticals  (NAS:PGNX) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Progenics Pharmaceuticals's Inventory Turnover for the three months ended in Mar. 2020 is calculated as

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Progenics Pharmaceuticals's Inventory to Revenue for the three months ended in Mar. 2020 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.


Progenics Pharmaceuticals Days Inventory Related Terms

Thank you for viewing the detailed overview of Progenics Pharmaceuticals's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.


Progenics Pharmaceuticals (Progenics Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
One World Trade Center, Suite J, 47th Floor, New York, NY, USA, 10007
Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.
Executives
Asha Das officer: Chief Medical Officer C/O PROGENICS PHARMACEUTICALS, INC., 1 WORLD TRADE CENTER, 47TH FL, SUITE J, NEW YORK NY 10007
Ann L. Macdougall director C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Karen Jean Ferrante director 150 ADIRONDACK DRIVE, EAST GREENWICH RI 02818
Heinz Christoph Maeusli director SCHUETZENWEG 3, ENGELBURG V8 9032
Gerard Ber director C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Eric J Ende director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Bradley L Campbell director C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Balaji Venkataraman 10 percent owner, other: See Explanation of Responses FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Virinder Nohria 10 percent owner, other: See Explanation of Responses 1055 POWERS PLACE, SUITE B, ALPHARETTA GA 30009
Nicole Williams director
David A Scheinberg director 325 CENTRAL PARK W, APT 38, NEW YORK NY 10025
Michael D Kishbauch director 18 CHERRYVILLE RD, FLEMINGTON NJ 08822
Broadfin Healthcare Master Fund Ltd 10 percent owner C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Kevin Kotler 10 percent owner C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Capital, Llc 10 percent owner 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022

Progenics Pharmaceuticals (Progenics Pharmaceuticals) Headlines

From GuruFocus